LOAD genetic risk loci and cognitive decline 2 Abstract Recent genome wide association studies have identified a number of single nucleotide polymorphisms associated with late onset Alzheimer's disease. Here we examine the associations of 24 LOAD risk loci, individually and collectively as a genetic risk score, with cognitive function. We used data from 1,626 non-demented older Australians of European ancestry who were examined up to four times over 12 years on tests assessing episodic memory, working memory, vocabulary and information processing speed. Linear mixed models were generated to examine associations between genetic factors and cognitive performance. Twelve SNPs were significantly associated with baseline cognitive performance (ABCA7, MS4A4E, SORL1), linear rate of change (APOE, ABCA7, INPP5D, ZCWPW1, CELF1) or quadratic rate of change (APOE, CLU, EPHA1, HLA, INPP5D, FERMT2). In addition, a weighted GRS was associated with linear rate of change in episodic memory and information processing speed. Our results suggest that a minority of AD related SNPs may be associated with non-clinical cognitive decline.
Introduction
Late onset Alzheimer's disease (LOAD), in which patients show clinical symptoms >65 years of age, is the most common form of dementia and the number of individuals with LOAD is expected to triple by 2050 [1] . LOAD has a long preclinical phase that commences decades before the onset of clinical symptoms, which are characterised by progressive degeneration of brain structure and chemistry resulting in gradual cognitive and functional decline [2] . The neuropathological hallmarks of LOAD are aggregation and accumulation of extracellular Amyloid-b peptides into amyloid plaques and accumulation of intraneuronal hyperphosphorylated and misfolded tau into neurofibrillary tangles. Accumulation of amyloid plaques and neurofibrillary tangles prompt the pathogenesis of AD by promoting alterations in lipid metabolism, neuroinflammation, endocytosis and synaptic dysfunction and loss that ultimately leads to neuronal cell death [3, 4] .
LOAD has a large genetic component, with the heritability estimated to be 60-80% [5] .
Apolipoprotein (APOE) epsilon 4 (*ε4) was the first common genetic variant to be identified [6] and remains the strongest genetic predictor of LOAD. Beyond APOE, recent genome-wide association studies (GWAS) and a meta-analysis by the International Genomics of Alzheimer's Project (IGAP) have identified single nucleotide polymorphisms (SNPs) at 23 loci associated with LOAD (ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A4A, MS4A4E, MS4A6A, PICALM, HLA-DRB5, PTK2B, SORL1, SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 and CASS4; [7] [8] [9] [10] [11] [12] ).
The identified LOAD risk loci are clustered in biological pathways that play an important role in disease onset and progression [13] and are involved in the accumulation of the pathological features of LOAD [14] . Furthermore, post-mortem analysis suggests that the neuropathological hallmarks of LOAD progress to varying degrees in individuals without dementia and are associated with cognitive status and nonclinical cognitive decline [15, 16] . LOAD risk genes are, therefore, good candidates for investigating potential genetic associations with cognitive performance and decline.
How these loci affect normal cognitive function may inform how they influence LOAD onset and progression.
This cross-over effect is exemplified by APOE, which is associated with LOAD and has effects on episodic memory, perceptual speed, executive functioning and global cognitive ability [17, 18] mediated predominantly by amyloid-β plaques [19] .
Association with cognitive decline of the first 11 LOAD risk loci identified by genomewide association studies (GWAS) are inconsistent [20] [21] [22] [23] [24] [25] [26] [27] . Whether the new risk loci identified by IGAP are associated with cognitive decline has yet to be extensively investigated [28] [29] [30] .
Here, we report associations of the 24 most significant LOAD risk loci with longitudinal change in cognitive performance (based on four neuropsychological outcomes) over 12 years in 1,626 community dwelling older adults. We investigate whether these loci are associated, either individually, or collectively as genetic risk scores (GRS), with: average differences in cognitive performance; rate of cognitive decline; and acceleration of the rate of decline over time.
Methods

Participants
Participants of this study are community dwelling older adults who were recruited into the Personality and Total Health (PATH) through life project, a longitudinal study of health and wellbeing. Participants in PATH were sampled randomly from the electoral rolls of Canberra and the neighbouring town of Queanbeyan into one of three cohorts based on age at baseline, the 20+ (20-24), 40+ (40) (41) (42) (43) (44) and 60+ (60-64) cohorts.
Participants are assessed at 4-year intervals, and data from 4 waves of assessment are available. The background and test procedures for PATH have been described in detail elsewhere [31] . Written informed consent for participation in the PATH project was , for a total of 12 years of follow-up. Individuals were excluded from analysis based on the following criteria: attendance at only 1 wave (n=309); no available genomic DNA (n=60); APOE ε2/ε4 genotype (n=60, to avoid conflation of the ε2 protective and ε4 risk affect); non-European ancestry (n=110); probable dementia at any wave (MMSE < 24; n=82); self-reported medical history of epilepsy, brain tumours or infections, stroke and transient ischemic attacks (n= 450). Missing values in "Education" (total number of years of education, n = 128) were imputed using the 'missForest' package in R [32] . This left a final sample of 1,626 individuals at baseline.
Cognitive Assessment
All participants were assessed at baseline and at each subsequent interview for the following four cognitive abilities: perceptual speed was assessed using the Symbol Digit Modalities Test, which asks the participant to substitute as many digits for symbols as possible in 90 seconds [33] ; episodic memory was assessed using the Immediate Recall of the first trial of the California Verbal Learning Test, which involves recalling a list of 16 nouns [34] ; working memory was assessed using the Digit Span Backward from the Wechsler Memory Scale, which presents participants with series of digits increasing in length at the rate of one digit per second and asks them to repeat the digits backwards [35] ; and vocabulary was assessed with the Spot-the-Word Test, which asks participants to choose the real words from 60 pairs of words and nonsense words [36] Raw cognitive test scores at each wave and Pearson's correlation between test scores are presented in Supplementary Tables 1 & 2 .
Genotyping
For this study, we used genotype data for 25 SNPs that have been associated with LOAD ( Table 1) . Genotyping of 11 GWAS LOAD risk SNPs (in the following loci: ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A4A, MS4A4E, MS4A6A and PICALM) using TaqMan OpenArray assays has been reported previously [20] . In this study 16 SNPs were selected for genotyping. These included the 12 LOAD GWAS SNPs, which were identified in a meta-analysis of the previous GWAS studies performed by IGAP (in the following loci: HLA-DRB5, PTK2B, SORL1, SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 and CASS4; [12] ). Three were associated with general cognitive function (MIR2113-rs10457441, AKAP6-rs17522122, TOMM40-rs10119; [28] . One was associated as a haplotype with LOAD (FRMD4A-rs2446581; [37] ). We used proxy SNPs that were in LD with four (HLA-DRB5/HLA-DRB1-rs9271192 [r 2 = 1], MEF2C-rs190982
[r 2 = 0.89], CELF1-rs10838725 [r 2 = 0.99] and CASS4-rs7274581 [r 2 = 0.99]) of the SNPs reported by IGAP, as Taqman assays were unavailable [12] .
Genomic DNA was extracted from cheek swabs (n = 2,192) using Qiagen DNA kits or from peripheral blood leukocytes (n = 101) using QIAamp 96 DNA blood kits. Pre-amplification of the targeted loci was performed using the TaqMan PreAmp Master Mix Kit (Life Technologies). Each reaction included 2.5µl TaqMan PreAmp Master Mix (2x), 1.25µl Pre-amplification Assay Pool, 0.5µl H20 and 1.2µl genomic DNA. These reactions were incubated in a Biorad thermocycler for 10 min at 95°C, followed by 12 cycles of 95°C for 15 sec and 60°C for 4 min, and then incubated at 99.9°C for 10 minutes. The PreAmplified products were then held at 4°C until they were diluted 1:20 in 1x TE buffer and then stored at -20°C until use.
Post-PreAmplification, samples were genotyped using the TaqMan OpenArray System. 2μl diluted pre-amplified product was mixed with 2µl TaqMan OpenArray Master Mix.
The resulting samples were dispensed using the OpenArray ® AccuFill TM System onto Participant-specific quality controls included filters for genotype success rate (> 90%) and sample provenance error assessed via pairwise comparisons of genotype calls between all samples to identify samples with > 90% similarity. Analysis of samples that were flagged in the initial quality control checks were repeated. Those samples that still failed quality control were excluded. SNP-specific filters included genotype call rate (> 90%) and Hardy-Weinberg equilibrium (p > 0.05) assessed using an exact test.
The two SNPs defining the APOE alleles were genotyped separately using TaqMan assays as previously described [38] . All SNPs were in Hardy-Weinberg equilibrium and genotype frequencies are reported in Supplementary Table 3 .
Data Preparation & Statistical Analysis
All analyses were performed in the R 3.2.3 Statistical computing environment [39] .
Cognitive tests at all 4 waves were transformed into z-scores (Mean = 0, SD = 1) using the means and SD at baseline to facilitate comparisons between cognitive tests. A higher score on all tests indicates better cognitive performance.
Genetic dominance was assumed for the previously reported risk allele for all SNPs, except SORL1, DSG2 and CASS4 where a recessive model of inheritance was assumed due to the low frequencies of the non-risk allele. The APOE *ε2 and APOE *ε4 alleles were assumed to be dominant to the APOE *ε3 allele. APOE alleles were coded as APOE *ε2+ (APOE *ε2/ε3 + APOE *ε2/ε2), APOE*ε4+ (APOE *ε4/ε3 + APOE *ε4/ε4) or APOE *ε3/ε3. Participants with the APOE *ε2/ε4 allele were excluded to avoid conflation between the APOE *ε2 protective and APOE *ε4 risk effects.
Three genetic risk scores were constructed [40] : (1) 
. For the above formulae, risk scores are calculated for the ith patient, where log( ! ) = the odds ratio for the jth SNP; !" = the minor allele frequency for the jth SNP; and !" = the number of risk alleles for jth SNP. SNPs were weighted by their previously reported OR for LOAD and by the minor allele frequency (MAF) reported by the International HapMap project for the CEU reference population (Table 1) . Participants missing genetic data for any SNP were excluded from GRS analysis (n = 121). All three GRS were transformed into zscores to facilitate comparison between them. A higher score indicates greater genetic risk.
Linear mixed effects models (LMMs) with maximum likelihood estimation and subjectspecific random intercepts and slopes were used to evaluate the effect of individual represented as orthogonal polynomials to avoid collinearity problems and facilitate estimation of the models [41] . Covariates included in the models were sex, total years of education and, for individual SNP models, APOE genotype. LMMs were estimated using the R package 'lme4' [42] . Statistical significance of the fixed effects was determined using a Kenward-Roger approximation for F-tests, where a full model, containing all fixed effects, is compared to a reduced model that excludes an individual fixed effect (R package 'afex' [43]). A p-value < 0.05 was considered statistically significant. We did not adjust for multiple testing as there is strong a priori evidence for all our hypotheses based on previous findings for validated LOAD susceptibility loci. Conditional R 2 ( ! ! ), the variance explained by fixed and random effects (i.e. the entire model), and marginal R 2 ( ! ! ), the variance explained by the fixed effects were calculated using the R package 'MuMIn' [44] [45] [46] by comparing a full model containing the predictor of interest to a reduced model excluding the predictor.
Results
Population characteristics of the PATH cohort
Demographic characteristics of the PATH cohort are presented in Table 5 ).
Main effects of LOAD GWAS SNPs
Introduction of the 24 LOAD GWAS risk loci into the LMMs ( Comparisons in the R 2 statistics between covariate only models and the SNPs showed that there was a negligible increase in marginal R 2 statistics and no increase in conditional R 2 statistics ( Supplementary Tables 6-29 ).
Main effects of LOAD GRS
We evaluated the association of three weighted genetic risk scores with cognitive performance ( Table 3 ; Supplementary Tables 30-32 ). Mean and SD for the raw GRS at baseline are presented in Table 1 . The SC-GRS was not associated with cognitive performance. Higher OR-and EV-GRS were associated with a greater rate of decline in Immediate Recall and Symbol Digit Modalities Test scores.
Comparisons in the R 2 statistics between covariates-only models and the GRS models showed that there was a negligible increase in marginal R 2 statistics and no increase in conditional R 2 statistics (Supplementary Tables 30-32 ). OR-and EV-GRS were not associated with cognitive performance when APOE was excluded from the GRS (Supplementary Tables 33-35 ).
Discussion
In this study we investigated the association of the 24 most significant LOAD GWAS risk Previous studies of association between the initial GWAS LOAD risk loci and cognitive performance are characterized by a lack of consistent findings. The limited number of studies that have examined the role of the IGAP LOAD risk loci in cognitive performance also produced mixed results [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [47] [48] [49] [50] [51] [52] [53] [54] [55] .
In univariate analysis, SNPs from 7 of the 23 non-APOE GWAS loci have been associated with cognitive performance. ABCA7 has been associated with declines in the MMSE score in women [30] . BIN1 has been associated with decline in MMSE score in one study [26] . CD2AP has been associated with a composite episodic memory in one study [48] .
CD33 has been associated with a composite executive function score [48] and decline in MMSE in women [30] . CLU has been associated with cognitive performance in four studies, with baseline episodic memory [21] , baseline and decline in a composite cognitive score [27, 53] and decline in 3MS [56] . CR1 has been associated with declines in verbal fluency [26] , global cognition [25, 52] , episodic memory, perceptual speed, semantic memory [54] and attention [56] . PICALM has been associated with a composite cognitive score [53] and decline in global cognition [24] . NME8 was associated with declines in Clinical Dementia Rating Scale Sum of Boxes Scores [55] .
In contrast to a univariate approach, aggregating SNP variation across genomic regions in a 'gene based' approach, has identified further AD risk loci as associated with cognitive performance. In a meta-analysis of 31 studies (n = 53,949), PICALM, MEF2C
and SLC24A4-RIN3 gene regions were associated with general cognitive function (p ≤0.05). In single sex cohorts, BIN1, CD33, CELF1, CR1, HLA cluster, and MEF2C gene regions were associated with decline in MMSE in a all female cohort and ABCA7, HLA cluster, MS4A6E, PICALM, PTK2B, SLC24A4, and SORL1 gene regions were associated with decline in 3MS in a all-male cohort.
Genetic risk scores can have greater predictive power than individual variants because they are based on the cumulative effect of many variants that individually may have effects that are too small to be reliably detected in a univariate analysis. GRS composed of genome wide significant LOAD SNPs identified in the initial LOAD GWAS have been associated with baseline general cognition [48] , episodic memory [21] , visual memory and MMSE [26] and with decline in episodic memory [21] , verbal fluency, visual memory and MMSE [26] . However these associations were no longer statistically significant when APOE was excluded from the GRS.
Two studies have investigated a GRS composed of the IGAP LOAD SNPs, one of which showed that a GRS with APOE excluded was associated with decline in MMSE in participants with MCI [29] . The second study showed that a GRS with APOE included was associated with memory performance at baseline and with a faster rate of decline that accelerated with age. However, after excluding APOE only linear rate of change remained significant [57] .
Genome-wide significant IGAP LOAD risk loci do not reflect the full spectrum of genetic susceptibility to LOAD risk loci, explaining only 30.62% of the genetic variance of LOAD [58] . Thus, an alternative approach is to construct a genome-wide polygenic score (GPS) which is calculated based not solely on genome-wide significant SNPs, but on all nominally associated variants at a given significance level. The first study to use this method did not find an association with cognitive ability or cognitive change [59] . A more recent study using data collected from the UK Biobank (n = 112 151) found that an AD GRS constructed from 20,437 SNPs that were associated with AD at a threshold of p < 0.05 in the IGAP study was significantly associated with lower verbal-numerical reasoning, memory and educational attainment [60] .
As noted above, the association of LOAD risk loci with cognitive performance is mixed.
Several factors may explain the discrepancies between studies. First, the failure to replicate positive results between studies could result from differences in participant characteristics (e.g., baseline education, mean age, gender, and ethnicity) and
methodologies (e.g., sample size, duration of the study, number of follow-ups, nonlinear time, population stratification, variation in classification, and cognitive measures [61] . In particular, studies that did not exclude cognitively impaired individuals from the analysis could bias the observed results in favour of a positive association [28, 62] .
Selectively removing from the analysis individuals who develop cognitive impairment during the study, as in this study, may not resolve the issue because of inadvertent inclusion of participants with preclinical dementia. This issue was highlighted in the study by Hassenstab et al, which reported that inclusion of individuals who were cognitively normal, but had biomarker and neuroimaging evidence of preclinical AD, greatly exaggerated age-related cognitive decline across multiple cognitive domains [63] . This finding suggests that AD-related genes may be associated with cognitive decline in participants who are in the preclinical stages of AD, and who if followed for long enough would develop AD. This has been observed in cognitively normal participants who had low levels of PET Aβ but were APOE *ε4+. This group remained cognitively stable, in comparison to an APOE *ε4+ group with high PET Aβ who experienced faster rates of cognitive, decline, suggesting that declines in cognitive function observed in APOE *ε4 carriers reflects the effect of APOE exacerbating Ab related cognitive decline rather then an independent APOE effect [64] . This effect is further indicated by previous studies showing that ABCA7, EPAH1 and CLU were associated with cognitive decline in participants classified as cognitively impaired or demented, but not in those who remained cognitively normal [20, 21, 51] .
Second, the rationale for including LOAD risk loci in the analysis is that they may be associated with biological processes, such as neurotic plaque or neurofibrillary tangle burden, that affect both LOAD and general cognitive performance. Only some LOAD risk loci are known to be associated with these pathological features. There may be a lack of association with cognitive performance because some loci are associated with LOAD for other reasons that do not affect general cognitive function.
Notably, of the 23 loci identified in the IGAP study, only 11 have been associated with neurotic plaque (ABCA7, BIN1, CASS4, MEF2C, PICALM, MS4A6A, CD33 and CR1) or neurofibrillary tangle (ABCA7, BIN1, CASS4, MEF2C, PICALM, CLU, SORL1 and ZCWPW1) burdens in AD case/control autopsies [52, 65] . In a longitudinal study, only BIN1 and CASS4 were associated with amyloid accumulation [66] . In contrast, in subjects with MCI, none of the LOAD risk loci were associated with levels of Aβ in the cerebrospinal fluid (CSF) and only SORL1 was associated with levels of tau and phosphorylated tau (components of neurofibrillary tangles) in the CSF. Finally, the pathogenesis of LOAD spans decades, clinically progressing through the preclinical, MCI and dementia stages. The underlying pathological process has been modelled as a cascade that starts with amyloidosis followed by hyperphosphorylated tau accumulation and subsequent structural, functional and cognitive declines [2] . As such, where and when a risk locus is involved in the LOAD pathogenesis cascade may influence whether it is associated with processes that predispose, initiate or propagate cognitive decline. Therefore, the lack of associations with cognitive performance with the majority of the LOAD risk loci in this study could indicate that they exert their pathological effects at latter stages. Associations have been reported between LOAD risk loci CD2AP, CLU, MS4A6A and INPP5D and progression from normal cognition to dementia [72] ; between CLU, CR1, and NME8 and progression from MCI to dementia [72] [73] [74] ; between INPP5D, MEFC2, EPHA1, PT2KB, FERMT2, CASS4 and rate of progression in AD [75] ; and between PICALM and MS4A6A and progression to MCI/Dementia from normal cognition normal [21] .
In the context of atypical AD, which is characterized by the development of nonamnestic cognitive deficits [76] , some LOAD SNPs may be associated with non-amnestic cognitive domains. As such, the lack of consensus across studies could result from participants being at different stages in the pathogenesis of AD and from assessment of different cognitive domains between studies.
The present findings need to be interpreted with an understanding of their limitations.
First, the PATH cohort is better educated then the population it was drawn from. As higher education is associated with a reduced risk of cognitive decline and incident dementia, this may limit our ability to detect an association between genetic factors and cognitive performance. Second, the subjects in this study were of European ancestry, and thus the results presented may not be generalizable to other populations. Third, even after retrospectively removing participants with cognitive impairment, this cohort may still contain individuals who are in the preclinical stages of AD and thus potentially biasing our results. Fourth, there may have been differential attrition from the PATH study of individuals who later became severely impaired and demented, which may have biased results because these individuals would not be excluded from our analysis and are more likely to experience faster rates of cognitive decline [77] . Finally, we had a prior expectation that each of the SNPs we analysed would be associated with cognitive decline because of its association with LOAD. We, therefore, did not correct for the effect of multiple comparisons. If we had applied a Bonferroni correction none of the observed associations would remain significant.
Despite these limitations, this study has a number of strengths. It was performed in a large community-based cohort that has been followed for a period of 12 years with four waves of data assessing four separate cognitive domains. This allows for robust statistical modelling of the association of genetic factors with non-linear declines across a broad spectrum of cognition functions. Additionally, the narrow age range of this cohort reduces the influence of age differences on the results.
In conclusion, our results suggest that a subset of AD-risk loci are associated with nonclinical cognitive decline, although the effect size of each locus is small. Further, when demographic and lifestyle factors are taken into account, neither individual SNPs nor GRS explain a significant proportion of the variance in cognitive decline in our sample.
Further investigation of the association of LOAD risk loci with cognitive function needs to account for the inclusion of participants with preclinical AD. The use of neuroimaging and cerebrospinal fluid biomarkers to determine preclinical AD status will allow for a more robust analysis of the role of LOAD risk loci in cognitive aging. 
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